California Public Employees Retirement System Buys 1,048 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

California Public Employees Retirement System boosted its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 3.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 32,150 shares of the medical research company’s stock after purchasing an additional 1,048 shares during the period. California Public Employees Retirement System’s holdings in Bio-Rad Laboratories were worth $10,562,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in BIO. Venturi Wealth Management LLC grew its position in shares of Bio-Rad Laboratories by 2,175.0% during the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock worth $30,000 after buying an additional 87 shares in the last quarter. Picton Mahoney Asset Management grew its holdings in Bio-Rad Laboratories by 55.6% during the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company’s stock worth $32,000 after acquiring an additional 35 shares in the last quarter. Asset Planning Inc purchased a new position in Bio-Rad Laboratories during the 4th quarter valued at about $33,000. UMB Bank n.a. raised its holdings in shares of Bio-Rad Laboratories by 41.6% in the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 32 shares in the last quarter. Finally, Cape Investment Advisory Inc. purchased a new stake in shares of Bio-Rad Laboratories in the 4th quarter worth approximately $38,000. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Price Performance

NYSE BIO opened at $225.21 on Monday. The firm’s fifty day simple moving average is $281.98 and its two-hundred day simple moving average is $319.24. The firm has a market capitalization of $6.31 billion, a P/E ratio of -3.46 and a beta of 1.12. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 12-month low of $221.18 and a 12-month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Wells Fargo & Company cut their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. StockNews.com lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Bio-Rad Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $395.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.